A drug development crossroad lies ahead

Similar documents
DMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION

CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE DMPK OVERVIEW XENOGRAFT MODELS ADME SUMMARY REPORT.

Your bridge to. better medicines

Novartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program

Finding the right partner for preclinical into phase I. Facts, Threats & Opportunities

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS

MODEL-BASED DRUG DEVELOPMENT: A FDA CRITICAL PATH OPPORTUNITY

EARLY PHASE DEVELOPMENT SOLUTIONS

QPS Neuropharmacology Overview

Career Growth Areas in Physiology / Pharmacology

The Right Molecules. Designed. Delivered.

UNLEASH THE POWER OF PRECISION MEDICINE

Effective Project Leadership and Management: Disclaimer

395 South Youngs Road Buffalo, New York cognigencorp.com An On-Site 2-Day Workshop in Engineering The Pharmacometric Enterprise

Envigo Corporate & Industry Overview. Rutgers University

Agreed with W. Cornell Graduate Program and Tri-I

SPEED UP YOUR TIME TO MARKET

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

ENHANCING CLINICAL DATA QUALITY WITH SPECIALIZED FUNCTIONAL SERVICE PROVIDER MODEL

1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Drug Discovery and Development Market in Asia - Introduction 3 Drug Discovery and

STARTING STRONGER IN PHASE I THROUGH IIA

Bachem Annual Report 2017

ESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Eurofins ADME BIOANALYSES Your partner in drug development

Explore the World of End-to-End. Integrated Lab Performance

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

So many science careers: find your own niche

FUTURE MEANS CREATIVITY

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program

Development of a new medicinal product. as. MUDr. Martin Votava, PhD.

ENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY

AT A GLANCE. inventivhealthclinical.com

Early Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development

PPD LABORATORIES COMPREHENSIVE SERVICES

CRO partner in Rx/CDx Co-Development

BREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D

May 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250

The Aptuit Center for Drug Discovery & Development Verona, Italy

An Introduction to Clinical Research and Development

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery

Introduction to Drug Design and Discovery

FACT SHEET. A CRA Perspective: The Difference between Medical Device Studies and Pharmaceutical Studies.

NUVISAN GROUP. Our Philosophy

Fast Track Drug Development The Clinical (Caleidoscopic) Perspective

Get to market. You want to develop medical devices that are safe, effective, and compliant. We ll show you the most efficient path.

Science. Enhancing the Pharma-CRO relationship with a focus on method transfer. for a safer world

21st Annual International Conference on Drug-Drug Interactions. Zach Mitts Northwest Account Manager

Can Scientific Integrity Be Protected When Outsourcing Early Phase Bioanalysis?

UBS Global Life Sciences Conference. September 26, 2006

DMPK Overview. DMPK Overview. CYP i NDUCTi ON. P r OTeiN Bi NDi NG. CYP i NHi B i T i ON. r ADi OLABe L MASS BALANCe. X e NOGr AFT MODe LS

OUR BUSINESS. A history of helping our clients develop more medicines worldwide than any other company, including THE TOP 50

Almac Overview.

From Bench to Bedside. Russ H. Read June 23, 2014

How to Choose the Right CMO for Your Pharmaceutical Product

博奥信生物技术 ( 南京 ) 有限公司. Biosion (China) Recruiting

BIOSTATISTICAL METHODS

BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH

Building Our Pipeline While Addressing Talent Needs: A University Rela;ons Model

Key Activities. Ofer Reizes, Ph.D. Skills Development Director

We offer integral tailor-made solutions, providing our expertise, flexibility and capability from early stages to launch.

Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities

Non-Dilutive Funding for Opportunities for CNS/PNS Related R&D

Speakers Title & Biography

The In Vitro Diagnostic CRO

Executive Search. Chief Standards Officer

Drug-Device Combination Product Development: INDs for Device Companies

A full-service CRO with integrated early-stage capabilities

2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award

Optimisation de votre programme de développement

NIH-RAID: A ROADMAP Program

HUMAN CHALLENGE TESTING

MDI Manufacturing Services

We set things in motion and keep them moving. Metronomia Clinical Research Services

Inflammatory Bowel Disease

Introduction of Development Center for Biotechnology TAIWAN

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey

Proof of Concept. Achieve your molecule s full potential

Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes

PART I PAST, PRESENT, AND FUTURE OF PEDIATRIC DRUG DEVELOPMENT COPYRIGHTED MATERIAL

2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships

Common Regulatory Issues for Stem Cell Products. Christopher A Bravery

Pharmaceutical Product Development NASDAQ: PPDI Fred Eshelman Chief Executive Officer

Pharmaceutical Product Development NASDAQ: PPDI Fred Eshelman Chief Executive Officer

International Conference on Pharmacy and Pharmaceutical Sciences April 09-11, 2018, Dubai UAE

Collaborations between pharma industry and academia as drivers for innovations

STRATEGIC RESOURCING. inventivhealthclinical.com

Supplementary Materials for

Strategic Outsourcing for Success

Antibody Discovery at Evotec

Establishment of Clinical Trial Infrastructure

Strategic Plan. Prepared by Onco Research July Version 3.1

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Cancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development

at a glance Lugano, 20 September 2013 LUGANO SMALL & MID CAP INVESTOR DAY > 50 years of Pharmaceutical & Life Science Services IV Edizione

Forward Thinking. American International Health Alliance Strategic Plan 2016 to 2021

Contact:: (609) Details please visit our website:

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

Company Report Daring to be different

Transcription:

G L O B A L C B O C O S T E F F E C T I V E B I O A N A L Y T I C A L H I G H Q U A L I T Y E A R L Y S T A G E C L I N I C A L T R A N S L A T I O N A L M E D I C I N E H I G H L Y C O M P E T E N T A C C E S S I B L E T R U S T I N G A drug development crossroad lies ahead In today s complicated world of pharmaceutical product development it is not always easy to find the right way. Many different routes may lead to your final destination. But are they all equally direct? Probably not, and that is where QPS comes in. No matter how far along your product is in its development, our professionals will steer you along the right path.

Find out how to achieve your next development milestone ahead of schedule Find out how you can benefit from working with an extremely competent, high-quality, yet cost effective and accessible global CRO that will go aboveand-beyond to build a trusting relationship with you. G L O B A L C B O P R E C L I N I C A L D I S C O V E R Y C L I N I C A L D R U G D E V E L O P M E N T Q U A L I T Y S E R V I C E S B I O T E C H N O L O G Y P H A R M A C E U T I C A L

Join the many pharmaceutical and biotech companies that count on QPS global team of >750 qualified and experienced professionals to speed up drug discovery and development programs in the following six key R&D areas: Thank you for the report and stability data. I will discuss the next steps for this with CC. May I take a chance to thank you (and your colleagues) for all your hard work over the last few months; I have been really pleased with the way you came through against the tight timelines. Carl W. Biomarker Assay Specialist (Clinical Assay Group) DMPK QPS offers you immediate access to a team of senior scientists with decades of pharmaceutical and biotech drug discovery and development experience. We walk you through the appropriate ADME studies across a broad range of compound structures and therapeutic targets. For many, especially virtual, small and mid-size pharmaceutical firms, outsourcing ADME studies to an experienced CRO such as QPS is a practical alternative to building or expanding in-house DMPK departments. Expanded expertise and improved cost-effectiveness are among the many compelling advantages of outsourcing to QPS. Toxicology QPS offers you comprehensive preclinical packages to support your IND and NDA regulatory submissions with high-quality toxicology data. Over the past two decades, we have performed over a thousand GLP studies for local and international pharmaceutical and biotechnology companies, covering many different disease therapies. This vast experience is a testament to our ability to effectively deliver high quality toxicology data to you, our valued customers. Why not take advantage of QPS depth and breadth of experience in providing GLP-compliant services at our preclinical site in Asia? Bioanalysis QPS offers you one of the world s largest capacities in bioanalysis for small molecules and biologics, with bioanalytical facilities in the USA, Europe, India and Taiwan. Find out how a strategic outsourcing alliance with QPS can provide you with world class operational and service excellence in bioanalysis and help save valuable time and money. Translational Medicine QPS offers you specialized biomarker assay capabilities in various therapeutic niche areas, which enable you to follow targeted therapies and personalized medicines. For instance, in Alzheimer s studies, QPS can help you - given the right selection and evaluation of biomarkers in early drug development - to minimize the time required to reach critical decision points on items such as proof of concept (POC), dosing, candidate selection, and development risks.

S C I E N T I F I C E X P E R T I C E R E S P E C T N A L Y T I C A L V O L U N T E E R W U R K D E V E L O P M E D I C N E S P L O Y E E S B E N E F I T P A T I E N T S B E N E F I C I A L P A R T N E R S H I P S P H Early Stage Clinical QPS offers you 400 phase I beds on three continents - 24 in the Netherlands, 40 in Taiwan, 92 in India and 240 in the USA. This is one of the world s largest phase 1 site offerings of any CRO. For the past 15 years, QPS phase I sites have collectively completed more than a thousand clinical trials involving tens of thousands of study volunteers. We have studied every conceivable kind of molecular entity, large or small, either being investigated as part of a complex, first-in-man program or a single, large bioequivalence study. QPS possesses the clinical pharmacology experience that is critical for speeding up your early clinical development process. Late Stage Clinical QPS offers you clinical research operations in the US, Netherlands, India, and Taiwan. Expand your global reach through QPS and contain your clinical development costs by making use of QPS world wide contract clinical staffing and pharmacometrics (including data management, biostatistics, PK/PD evaluation and medical writing) capabilities. Our Vision We partner with our clients to discover and develop medicines that will benefit patients worldwide, and we foster strong ties to our communities through charitable contributions and volunteer work. QPS promotes a work-life balance by providing a fair, safe, ethical, familyfriendly, respectful and caring work environment. Because of this, we attract and retain dedicated and motivated employees through career growth opportunities, recognition for their contributions, and financial rewards. We seek mutually beneficial partnerships through an integrative approach to best serve our stakeholders and keep the stakeholders needs in focus while cultivating trust and mutual respect for our partners.

QPS is a reputable and profitable provider of world-class pharmaceutical development services, possessing unparalleled scientific expertise within our core competencies. From left to Right: Level 1: Jerry Gromelski, Irma Scheepstra, Level 2: Jeff Moran, Edwin van Vulpen, Livia Legg, Andrew Nehls, Lily Rosa, Jelle Hempenius, Marina Abanto, Mary Ann Gagnon, Brendon Bourg, Level 3: Jim Cunningham, Wendy Nelson Time is of the essence, so contact a member of the QPS Business Development Team today and find out what QPS can do for you North America Asia Europe DMPK, Bionalysis & Translational Medicine - Northeast: Wendy Nelson +1 508 543 0228 wendy.nelson@qps-usa.com - Mid Atlantic: Jerry Gromelski +1 570 451 3015 jerry.gromelski@qps-usa.com - Southeast: Marina Abanto +1 513 232 4772 marina.abanto@qps-usa.com - Central: Jim Cunningham +1 402 541 6041 jim.cunningham@qps-usa.com - West Coast: Jeff Moran +1 302 690 2163 jeff.moran@qps-usa.com Early & Late Stage Clinical - Andrew Nehls +1 402 895 2022 andrew.nehls@qps-usa.com - Central: Jim Cunningham +1 402 541 6041 jim.cunningham@qps-usa.com - West Coast: Jeff Moran +1 302 690 2163 jeff.moran@qps-usa.com Toxicology - Dave Dehler +1 540 751 1325 dave.dehler@qps-usa.com - Alex Chang (Taiwan) +886 2 2655 7555 alex.chang@qps-taiwan.com.tw - Manish Kalwani (India) +91 40 2377 0873 74 manish@bioserve.co.in - Alex Chang (Japan) +886 2 2655 7555 alex.chang@qps-taiwan.com.tw - Alex Chang (Other Asian Countries) +886 2 2655 7555 alex.chang@qps-taiwan.com.tw HQ BD Office DMPK, Toxicology, Bionalysis & Translational Medicine - Jelle Hempenius +31 50 304 8000 jelle.hempenius@qps.com Late Stage Clinical - Irma Scheepstra +31 50 304 8000 irma.scheepstra@qps.com Early Stage Clinical - Edwin van Vulpen +31 50 304 8000 edwin.van.vulpen@qps.com - Lily Rosa (USA) +1 512 350 2827 info@qps-usa.com

Call to arrange for a tour at one of QPS worldwide locations today NETHERLANDS USA TAIWAN INDIA QPS Taiwan QPS CTPS QPS Qualitix QPS Bio-Kinetic QPS HQ QPS Netherlands QPS Bioserve